Cox multivariate analysis for OS
| OS . | HR . | 95% CI . | P . | FDR-adjusted P . |
|---|---|---|---|---|
| Treatment group | ||||
| HMA vs IC | 1.68 | 0.95-2.98 | .076 | .076 |
| HMA + VEN vs IC | 0.31 | 0.12-0.83 | .019 | .038 |
| ELN risk group | ||||
| Intermediate vs favorable | 1.18 | 0.59-2.36 | .635 | — |
| Adverse vs favorable | 1.30 | 0.80-2.13 | .293 | — |
| Age at diagnosis, y | 1.04 | 1.02-1.06 | <.0001 | — |
| Secondary AML | 1.37 | 0.76-2.48 | .302 | — |
| ECOG performance status | ||||
| ≥2 vs <2 | 1.79 | 1.16-2.76 | .009 | — |
| FLT3-ITD | ||||
| Positive vs negative | 1.55 | 1.09- 2.21 | .016 |
| OS . | HR . | 95% CI . | P . | FDR-adjusted P . |
|---|---|---|---|---|
| Treatment group | ||||
| HMA vs IC | 1.68 | 0.95-2.98 | .076 | .076 |
| HMA + VEN vs IC | 0.31 | 0.12-0.83 | .019 | .038 |
| ELN risk group | ||||
| Intermediate vs favorable | 1.18 | 0.59-2.36 | .635 | — |
| Adverse vs favorable | 1.30 | 0.80-2.13 | .293 | — |
| Age at diagnosis, y | 1.04 | 1.02-1.06 | <.0001 | — |
| Secondary AML | 1.37 | 0.76-2.48 | .302 | — |
| ECOG performance status | ||||
| ≥2 vs <2 | 1.79 | 1.16-2.76 | .009 | — |
| FLT3-ITD | ||||
| Positive vs negative | 1.55 | 1.09- 2.21 | .016 |
FDR, false discovery rate.